Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HURA
Strong SellSinkerTuHURA Biosciences, Inc. · Healthcare · United States · $134M · Avg Vol: $504K/d
COMPANY DESCRIPTION
TuHURA Biosciences, Inc. is a clinical-stage oncology company developing novel immunotherapies to transform cancer treatment, having recently completed a de-SPAC transaction. The company focuses on leveraging its proprietary technologies to stimulate anti-tumor immune responses. Its innovative approach targets challenging cancers with the potential for improved patient outcomes.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 13.5M | — |
| EPS | -0.58 | -0.77 | -2.47 | -1.21 | -0.63 | — | -0.54 | -0.53 | -0.61 | — |
| Shares | 42.0M | 42.0M | 42.0M | 42.3M | 59.3M | +41.2% | 63.7M | — | — | — |
| Debt | 0.6M | 0.1M | 2.3M | 0.2M | 0.7M | 2.1% | 9.2M | — | — | — |
| Equity | -0.7M | 12.3M | -1.6M | 14.6M | 20.9M | 19.4% | — | — | — | — |
| Op CF | -6.6M | -7.5M | -12.0M | -14.7M | -27.6M | — | -29.7M | — | — | — |
| Inv CF | -3.3K | -36.3K | -1.3M | -6.1M | -1.3M | — | — | — | — | — |
| Fin CF | 7.0M | 16.3M | 2.7M | 29.8M | 19.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HURA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HURA | TuHURA Biosciences, Inc.(you) | $134M | 6 | Strong Sell |
| INO | Inovio Pharmaceuticals, Inc. | $133M | 3 | Strong Sell |
| GNLX | Genelux Corporation | $120M | 4 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| CBUS | Cibus, Inc. | $126M | 2 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 5 | Strong Sell |
| 2592.HK | Cloudbreak Pharma Inc. | $136M | 1 | Strong Sell |
| CNTB | Connect Biopharma Holdings Limited | $140M | 10 | Strong Sell |
| NAUT | Nautilus Biotechnology, Inc. | $113M | 4 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 11 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%